Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tert-Butylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 17/20 | 0.49 |
| ▸ | PPARG | P37231 | 15/20 | 0.49 |
| ▸ | PPARD | Q03181 | 8/20 | 0.49 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3959985 | 0.96 | PPARA (0.52) | PPARAPPARGPPARDTRPM8LTB4R2 | |
| SCHEMBL4898468 | 0.96 | PPARA (0.52) | PPARAPPARGPPARDTRPM8LTB4R2 | |
| SCHEMBL3964011 | 0.93 | PPARA (0.51) | PPARAPPARGPPARDTRPM8LTB4R2 | |
| Tert-Butylamine SCHEMBL3963133 | 0.91 | TRPM8 (0.55) | PPARAPPARGPPARDTRPM8 | |
| Tert-Butylamine SCHEMBL3963631 | 0.90 | PPARA (0.47) | PPARAPPARGPPARDTRPM8LTB4R2 | |
| SCHEMBL3962992 | 0.90 | PPARA (0.52) | PPARAPPARGPPARD | |
| SCHEMBL3963050 | 0.89 | PPARA (0.57) | PPARAPPARGPPARDTRPM8 | |
| SCHEMBL3964001 | 0.88 | TRPM8 (0.45) | PPARAPPARGPPARDTRPM8LTB4R2 | |
| SCHEMBL3956914 | 0.88 | PPARA (0.54) | PPARAPPARGPPARD | |
| SCHEMBL3962831 | 0.87 | PPARA (0.49) | PPARAPPARGPPARDLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488844-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2009-02-10 | — | — | US | disclosed |
| US-7462644-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2008-12-09 | — | — | US | disclosed |
| US-20050282822-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | US | disclosed |
| EP-1572626-A1 | THERAPEUTIC AGENTS | Astrazeneca AB (SE) | 2005-09-14 | — | — | EP | disclosed |
| US-20050131068-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
| WO-2004056748-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131068-A1 | Therapeutic agents | GPR119, INSR, LIPA | PPARA 539/4885PPARG 479/4885PPARD 698/4885 |
| US-20050282822-A1 | Therapeutic agents | GPR119, LIPC, PNLIP | PPARA 346/4885PPARG 228/4885PPARD 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.